Four things to know:
1. In November 2018, Bioventus disclosed to the OIG that its sales representatives completed Section B of the certificates of medical necessity for its Exogen devices, which should be completed by the physician or physician’s office.
2. The company found sales representatives improperly completed some of the forms billed for from Oct. 1, 2012, to Sept. 30, 2018.
3. Bioventus reviewed medical records of the devices used in cases where sales representatives filled out the forms to verify medical necessity.
4. Bioventus agreed to pay more than $3.6 million to resolve the allegations Feb. 25.
More articles on orthopedic devices:
NuVasive Q4 sales dip 6%, submits Pulse for approval: 6 notes
Medtronic to expand spinal robotic capabilities after record 3rd-quarter sales
Aurora Spine the latest company to launch sacroiliac joint system
